Tax, audit and advisory firm KPMG announced a collaboration with generative AI company Hippocratic AI to use its agents to address global workforce shortages.
Hippocratic AI’s Polaris Constellation architecture includes generative AI healthcare agents aimed at helping with a range of healthcare workflows from patient intake to care management follow-up calls.
In a statement, KPMG said it is conducting comprehensive process analyses to pinpoint high-pressure points and upskill workforces, helping to expand the workforce with AI and “strategically plan for the highest-impact deployment of AI across the entire care continuum.”
The aim is for Hippocratic’s generative AI agents to free up provider time by using conversational agents designed to interact with humans naturally and intuitively.
The company says its agents comprehend, process and respond to human conversation in a contextually relevant and human-like behavior.
“Hippocratic AI’s collaboration with KPMG is deeply aligned in purpose and vision,” Munjal Shah, founder and CEO of Hippocratic AI, said in a statement.
“Their holistic approach to digital and clinical transformation focuses on improving patient outcomes and optimizing healthcare efficiency. We appreciate their commitment to driving meaningful impact across the entire care journey with generative AI, while preserving the human touch of clinicians and the integrity of healthcare operations.”
THE LARGER TREND
In June, Hippocratic AI and Universal Health Services (UHS) announced that genAI agents, which support clinicians by making phone follow-up outreach to patients after discharge, have were deployed in two UHS subsidiaries: Summerlin Hospital Medical Center in Las Vegas and Texoma Medical Center in Denison, Texas.
The initiative aimed to support clinicians in continuing to monitor their patients after discharge from the hospital, detecting and alerting UHS clinical staff to changes in patient conditions and addressing patients’ questions.
In May, Hippocratic AI partnered with Eucalia, a clinical operations company, to launch the first Japanese-language genAI healthcare agent for non-diagnostic, patient-facing clinical tasks. The partnership marked Hippocratic AI’s entry into the Japanese market.
Scheduled to be introduced this year, the Japanese generative AI healthcare agent aims to support clinicians by taking on time-consuming but important non-diagnostic patient-facing tasks, including appointment scheduling, follow-up outreach, chronic care check-ins and medication adherence support.
In April, Hippocratic AI partnered with Burjeel Holdings, a healthcare services provider based in the United Arab Emirates. Burjeel Holdings operates in parts of the Middle East and North Africa.
Through the alliance, Hippocratic AI’s agents will be developed for “patient-facing non-diagnostic clinical tasks,” distributed across Burjeel Holdings’ healthcare facilities and physiotherapy clinics in the UAE and Oman.
In January, Hippocratic AI closed a $141 million Series B round, bringing its valuation to $1.64 billion. The company said the capital would be used to expand into new markets, including the pharmaceutical and payer sectors, as well as new geographies, such as EMEA, Latin America and Southeast Asia.
Last year, Hippocratic AI was issued its first patent by the U.S. Patent Office, which incorporated the company’s LLM innovations into its safety-focused LLM, built with a constellation architecture Polaris.
About the Author
